HC Wainwright Issues Pessimistic Estimate for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at HC Wainwright dropped their FY2028 EPS estimates for shares of BioCryst Pharmaceuticals in a report released on Thursday, May 7th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $0.29 per share for the year, down from their prior estimate of $0.39. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is $0.31 per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2029 earnings at $0.86 EPS and FY2030 earnings at $2.18 EPS.

A number of other analysts have also commented on BCRX. Evercore began coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target for the company. Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Citizens Jmp boosted their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.70.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $9.02 on Monday. The firm has a market capitalization of $2.29 billion, a PE ratio of -5.07 and a beta of 0.57. The firm has a fifty day simple moving average of $9.16 and a two-hundred day simple moving average of $7.91. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The business had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 EPS.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Phocas Financial Corp. purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $1,956,000. Vanguard Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 6.1% in the 3rd quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after buying an additional 1,246,633 shares during the last quarter. Aberdeen Group plc purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $7,126,000. Public Sector Pension Investment Board purchased a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth about $2,010,000. Finally, GSA Capital Partners LLP boosted its holdings in shares of BioCryst Pharmaceuticals by 70.7% in the 3rd quarter. GSA Capital Partners LLP now owns 190,294 shares of the biotechnology company’s stock worth $1,444,000 after buying an additional 78,827 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.